Jaume Amat, CEO of Specipig, new president of CataloniaBio & HealthTech Blog Post

CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The new entity, located at the Barcelona Science Park, represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.

 

EIT Health Wild Card: €4 million in search of innovative health ideas Blog Post

Under the new Wild Card programme, EIT Health consortium –the largest European body for innovation in healthy living and active ageing– has announced €4 million in funding for disruptive initiatives that help transform European healthcare and mitigate the social and economic impact of the progressive ageing of the population. The Universitat de Barcelona (UB), a core partner and promoter of EIT Health Spain, is one of the 14 European institutions that will offer advisory and incubation services to the two winning teams to turn their ideas into a business plan through of the Barcelona Entrepreneurship Institute (BIE), the Bosch i Gimpera Foundation (FBG) and the Barcelona Science Park (PCB). On Monday, January 29, an informative session will take place at the PCB.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

Presenting CataloniaBio & HealthTech Blog Post

A new era for the CataloniaBio association of companies and the HealthTech Cluster. Members of the two organisations unanimously passed the motion to merge under the brand CataloniaBio & HealthTech at their respective extraordinary general meetings held in Barcelona yesterday.The headquarters will be located at the Barcelona Science Park. It will promote the convergence of biopharma, MedTech and digital health companies to boost competitiveness and address unmet medical needs 

 

Cebiotex launches a €650,000 crowdfunding campaign to ensure that its oncological treatment reaches paediatrics Blog Post

Cebiotex—with headquarters in the Barcelona Science Park (PCB)—has launched an equity crowdfunding campaign of €650,000 through Capital Cell to ensure that its first drug, CEB-01, used in the local post-surgical treatment of soft tissue sarcomas, also reaches paediatric oncology. CEB-01 is the first therapeutic application of its innovative technology, which are based on nanofibres, for local drug delivery. In the future, however, the company aims to develop new applications for pancreatic and liver cancer, as well as glioblastoma.Since it was formed in 2012, Cebiotex has raised over €2 million from public and private funds. The success of the previous equity crowdfunding campaigns and the participation of impactful social investors has allowed Cebiotex to maintain a paediatric focus as one of the company’s strategic objectives.

 

Closing in on advanced prostate cancer Blog Post

A team headed by Xavier Salvatella, ICREA researcher from the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park, has discovered a new avenue through which to attack prostrate cancer cells that have developed drug-resistance. Published in the journal Structure, part of the Cell group, the study has involved Angel R. Nebreda’s lab and the Experimental Bioinformatics Lab, both at IRB Barcelona, and also the University of Barcelona.  

 

IBEC researchers show that physical forces activate genes involved in cancer Blog Post

IBEC’s researchers at PCB, led by Pere Roca-Cusachs, reveal how forces trigger the expression of certain genes by increasing the activity of a protein called YAP in the nucleus of the cell.  The results of the study, published in Cell, have shown how these forces ‘switch on’ the expression of genes that may result in cancer.